Formulation Development
ProtaGene Names Pharmaceutical Industry Leader Raymond Kaiser as CEO to Drive Next Stages of Growth
ProtaGene GmbH recently announced the appointment of Raymond Kaiser, PhD, as Chief Executive Officer. Ray will drive the continued innovation….
Roquette Expands Global Reach of Plant-Based Excipients Portfolio With Complete Acquisition of Crest Cellulose
Roquette recently announced its complete acquisition of India-based excipient manufacturer, Crest Cellulose. Following its purchase of a majority share in the company in 2018, this latest move….
Immunic Announces Positive Results from Single & Multiple Ascending Dose Parts of its Phase 1 Clinical Trial
Immunic, Inc. recently announced positive unblinded safety, tolerability and pharmacokinetic (PK) results from Part A (single ascending doses, SAD) and Part B (multiple ascending doses, MAD)…
Decibel Therapeutics Announces Submission of IND Application for Lead Gene Therapy Candidate
Decibel Therapeutics recently announced the submission of an Investigational New Drug (IND) application to the US FDA for a Phase 1/2 clinical trial in pediatric…
Evoke Pharma Receives Notice of Allowance From USPTO for a Patent Related to GIMOTI
Evoke Pharma, Inc. recently announced the USPTO issued a Notice of Allowance for US Application No. 16/469,092 for GIMOTI. When granted, the patent will cover…
Merck Joins Accumulus Synergy as a Sponsor to Transform the Global Drug Regulatory Submission Process
Accumulus Synergy recently announced Merck, known as MSD outside the US and Canada, has joined Accumulus Synergy as a sponsor company…..
GENFIT to Acquire Clinical-Stage Biopharmaceutical Company, Expanding its Portfolio in Liver Diseases
GENFIT recently announced it has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private…
RIGImmune Announces Acquisition of Antiviral Company Subintro
RIGImmune Inc. recently announced the acquisition of Subintro, a biotechnology company specializing in the development and delivery of antiviral therapeutics for respiratory diseases caused by…
Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
Excision BioTherapeutics, Inc. recently announced the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1)…..
WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms
Synchronizing and controlling API delivery, extrusion-spheronization (E-S) offers pharmaceutical companies a robust technique to manufacture today’s most complex therapeutics.
RQM+ Acquires Jordi Labs
RQM+ recently announced the acquisition of Jordi Labs. With these new capabilities, RQM+ provides comprehensive regulatory, quality, clinical, and laboratory services, supporting market….
Lonza Expands HPAPI Multipurpose Suite for Payload-Linker Manufacturing in Visp (CH)
Lonza recently announced the completion of the expansion of its Highly Potent API (HPAPI) multipurpose suite in Visp (CH). The expansion adds development and manufacturing…
Oxford Biomedica Solutions Signs Agreement With New Partner to Deliver the Full Solution for Its AAV Programs
Oxford Biomedica Solutions LLC recently announced it has signed an agreement with an undisclosed US-based private biotechnology company. The agreement will provide The Full Solution…
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
Cidara Therapeutics, Inc. recently announced the initiation of its Phase 2a trial to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus…..
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine
Vaxxinity, Inc. recently announced the first subjects have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP),…
Bryn Pharma Announces Completion of its Pivotal Study Comparing UTULY Epinephrine Intranasal Spray Versus 0.3-mg Epinephrine Autoinjector for the Treatment of Anaphylaxis
Bryn Pharma LLC recently announced the completion of its pivotal study of UTULY (epinephrine nasal spray). The primary objective of the study was to evaluate whether…
Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma
Nuvectis Pharma, Inc. recently announced positive data for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma. “Following the strong preclinical proof of concept…
SiSaf Announces Positive Preclinical Data for its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
SiSaf Ltd, an RNA delivery and therapeutics company, recently announce positive data confirming safety and efficacy of its Bio-Courier next-generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an….
Aptose’s New G3 Formulation of Luxeptinib Boosts Bioavailability
Aptose Biosciences Inc. recently announced the G3 formulation of luxeptinib, designed for rapid and efficient absorption, demonstrates approximately an 18-fold improvement in oral bioavailability….
Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial
Revolo Biotherapeutics recently announced it has completed enrollment and has fully randomized all patients in a Phase 2a proof of concept clinical study investigating its…